



SOUTH CAROLINA REVENUE AND FISCAL AFFAIRS OFFICE
STATEMENT OF ESTIMATED FISCAL IMPACT
(803)734-3780 • RFA.SC.GOV/IMPACTS

This fiscal impact statement is produced in compliance with the South Carolina Code of Laws and House and Senate rules. The focus of the analysis is on governmental expenditure and revenue impacts and may not provide a comprehensive summary of the legislation.

Bill Number:	H. 4568	Introduced on January 11, 2022
Author:	Oremus	
Subject:	Chemically-Induced Abortions, Disclosure Requirements	
Requestor:	House Judiciary	
RFA Analyst(s):	Wren	
Impact Date:	April 12, 2022 Updated for Additional Agency Response	

Fiscal Impact Summary

This bill requires a disclosure statement to be provided to a pregnant woman who is administered, dispensed, or otherwise provided mifepristone, which is the first drug used in a two-drug process to induce a chemical abortion. The disclosure statement must include specified language regarding misoprostol, which is the second drug used in a two-drug process to induce a chemical abortion.

This bill will have no expenditure impact on the Department of Health and Environmental Control (DHEC) since it does not alter the duties or responsibilities of the agency.

This bill will have no expenditure impact on the Department of Health and Human Services (HHS) since any expenditures resulting from the additional disclosure of medical information to patients will be minimal and can be managed within existing appropriations. Further, HHS indicates that the bill will have no impact on the Medicaid program.

This impact statement has been updated to include a response from HHS.

Explanation of Fiscal Impact

Updated for Additional Agency Response on April 12, 2022

Introduced on January 11, 2022

State Expenditure

This bill requires a disclosure statement to be provided to a pregnant woman who is administered, dispensed, or otherwise provided mifepristone, which is the first drug used in a two-drug process to induce a chemical abortion. The disclosure statement must include specified language regarding misoprostol, which is the second drug used in a two-drug process to induce a chemical abortion. The disclosure statement must be attached to the package that contains the misoprostol, attached to a written prescription for misoprostol, or attached to the patient's discharged instructions if misoprostol is sent directly to the pharmacy.

Department of Health and Environmental Control. DHEC indicates that this bill does not alter the duties or responsibilities of the agency. Therefore, the bill will have no expenditure impact on the agency.

Department of Health and Human Services. HHS indicates that any expenditure impact due to the additional disclosure of medical information to patients will be minimal and can be managed within existing appropriations. Further, the agency indicates that the bill will have no impact on the Medicaid program. Therefore, the bill will have no expenditure impact on HHS.

This section of the impact statement has been updated to include a response from HHS.

State Revenue

N/A

Local Expenditure

N/A

Local Revenue

N/A

Introduced on January 11, 2022

State Expenditure

This bill requires a disclosure statement to be provided to a pregnant woman who is administered, dispensed, or otherwise provided mifepristone, which is the first drug used in a two-drug process to induce a chemical abortion. The disclosure statement must include specified language regarding misoprostol, which is the second drug used in a two-drug process to induce a chemical abortion. The disclosure statement must be attached to the package that contains the misoprostol, attached to a written prescription for misoprostol, or attached to the patient's discharged instructions if misoprostol is sent directly to the pharmacy.

Department of Health and Environmental Control. DHEC indicates that this bill does not alter the duties or responsibilities of the agency. Therefore, the bill will have no expenditure impact on the agency.

Department of Health and Human Services. We have reached out to HHS to determine if this bill will have an impact on the Medicaid program. Therefore, the expenditure impact is pending, contingent upon a response.

State Revenue

N/A

Local Expenditure

N/A

Local Revenue

N/A



Frank A. Rainwater, Executive Director